文献速递肿瘤 PET/CT神经核医学

脑[18F]FDG摄取预测晚期非小细胞肺癌生存

Brain Metabolic Activity Measured by [18F]FDG PET/CT Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · J Nucl Med · 2026-07-01

该回顾性研究纳入2010至2023年接受治疗前[18F]FDG PET/CT的晚期NSCLC患者,分为发现集234例和测试集146例。发现集中高脑SUVmean与更长总生存相关(HR 0.83,95%CI 0.76-0.92,P<0.001),多变量分析显示脑SUVmean为独立预后因素(HR 0.89,95%CI 0.80-0.98,P=0.02),并在测试集得到验证。

要点

  • 高脑SUVmean与晚期NSCLC患者更长总生存相关
  • 脑SUVmean是多变量分析中的独立预后因素
  • 脑SUVmean与肿瘤影像组学特征无关,与部分血液标志物互补

核心结论

  • 低脑代谢活性与晚期NSCLC患者死亡率增加相关。
  • 脑SUVmean是独立预后因素,可能有助于患者分层,但其解读仍需进一步研究。

研究设计与样本

  • 回顾性研究,纳入2010至2023年间接受治疗前[18F]FDG PET/CT的晚期NSCLC患者。
  • 患者按时间顺序分为发现集(n=234;平均年龄64±11岁)和测试集(n=146;平均年龄66±11岁)。
  • 收集临床和生物学数据、肿瘤影像组学特征及脑SUVmean,采用单变量和多变量Cox回归评估总生存预测能力。

主要发现

  • 发现集中,高脑SUVmean(大于或等于中位数)与更长总生存相关(HR 0.83;95%CI 0.76-0.92;P<0.001)。
  • 1年内死亡患者脑SUVmean中位数显著低于同期仍存活者(4.9±1.4 vs. 5.7±1.5;P<0.001)。
  • 多变量分析显示脑SUVmean为总生存独立预后因素(HR 0.89;95%CI 0.80-0.98;P=0.02),并在测试集得到验证(P<0.001)。
  • 脑SUVmean与量化肿瘤累及的影像组学特征无关(r<0.24,n=380),与C反应蛋白等血液标志物显著相关但互补(r=-0.37,n=110例患者)。
  • 无脑转移患者中脑SUVmean的预后意义持续存在(P<0.001)。

临床怎么用

  • 在晚期NSCLC患者治疗前[18F]FDG PET/CT中,可关注脑SUVmean作为潜在预后分层指标。
  • 脑SUVmean的解读需结合临床背景并进一步研究验证。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[18F]FDG PET/CT images play a key role in the management of patients with non-small cell lung cancer (NSCLC). In these scans, the focus is on detected tumors and their characteristics, neglecting information from other organs or tissues. We investigated whether the mean brain [18F]FDG uptake (brain SUVmean) is associated with overall survival (OS) in patients with advanced NSCLC. Methods: This retrospective study included patients with advanced NSCLC who underwent pretreatment [18F]FDG PET/CT scans between 2010 and 2023. Clinical and biologic data, tumor radiomic features, and brain SUVmean were collected. The ability of these features to predict OS was evaluated using univariable and multivariable Cox regression models. The correlation between brain SUVmean and clinical, imaging, and blood biomarkers was investigated using Spearman correlation coefficients. Results: Patients were chronologically divided into a discovery set (n = 234; mean age, 64 ± 11 y) and test set (n = 146; mean age, 66 ± 11 y). In the discovery set, univariable analysis showed that high brain SUVmean (greater than or equal to the median) was associated with longer OS (hazard ratio [HR], 0.83; 95% CI, 0.76-0.92; P < 0.001). Brain SUVmean was significantly lower in patients who died within 1 y compared with those who were still alive at the same time point (median brain SUVmean, 4.9 ± 1.4 vs. 5.7 ± 1.5, respectively; P < 0.001). Multivariable analysis revealed that brain SUVmean was an independent prognostic factor for OS (HR, 0.89; 95% CI, 0.80-0.98; P = 0.02), which was confirmed in the test set (P < 0.001). Brain SUVmean was independent of the radiomic features quantifying tumor involvement (r < 0.24, n = 380) and significantly correlated but complementary to several blood biomarkers including C-reactive protein (r = -0.37, n = 110 patients). The prognostic significance of brain SUVmean persisted in patients without brain metastases (P < 0.001). Conclusion: Low brain metabolic activity was associated with increased mortality in patients with advanced NSCLC. Brain SUVmean was an independent prognostic factor that may aid in patient stratification, although its interpretation requires further investigation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Auriac J, Lemoudda G, Hovhannisyan-Baghdasarian N, et al. Brain Metabolic Activity Measured by [18F]FDG PET/CT Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer. J Nucl Med. 2026. PMID: 41956561. doi:10.2967/jnumed.125.271400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。